Business
InflaRx Announces Participation in September Investor Conferences
JENA, Germany, Aug. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor conferences in September 2025. Details are as follows: Cantor Global Healthcare Conference 2025September 3 - 5, 2025 in New York, NYFireside chat on September 4th at 9:10 AM ET InflaRx will also conduct one-on-one investor meetings on September 4th. A link to view
About this update from Inflarx N.v.
[{"type":"image","alt":"InflaRx N.V.","displaySize":"","headline":null,"caption":"InflaRx N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/105c0226a90fc647941f68c2de55213a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lqiU0gFIS0tiIdhYPTjZSw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/105c0226a90fc647941f68c2de55213a","width":300,"height":157}},"lazy":false},{"type":"text","content":"JENA, Germany, Aug. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor conferences in September 2025. Details are as follows:","length":290,"tagName":"p"},{"type":"text","content":"Cantor Global Healthcare Conference 2025September 3 - 5, 2025 in New York, NYFireside chat on September 4th at 9:10 AM ET","length":123,"tagName":"p"},{"type":"text","content":"InflaRx will also conduct one-on-one investor meetings on September 4th. A link to view the fireside chat live stream and its replay is available here.","length":151,"tagName":"p"},{"type":"text","content":"H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 8 - 10, 2025 in New York, NYPresentation on September 9th at 3:30 PM ET","length":139,"tagName":"p"},{"type":"text","content":"InflaRx will also conduct one-on-one investor meetings on September 9th. A link to register for the presentation live stream and its replay is available here.","length":158,"tagName":"p"},{"type":"text","content":"About InflaRx","length":13,"tagName":"p"},{"type":"text","content":"InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5a receptor technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple...